Lonza bone marrow and cord blood mononuclear cells

Monday, 18 April, 2011 | Supplied by: Capsugel Australia Pty Ltd

Lonza’s bone marrow and cord blood mononuclear cells are prepared by centrifugation in a density cell separation medium (Ficoll-Paque, Amersham Pharmacia).

Isolating the mononuclear cells eliminates erythrocytes and granulocytes, producing a more stable cell product.

Mononuclear cells can be used directly in hematopoietic assays or as the starting material for isolating CD34+ progenitor cells.

Cells are available cryopreserved with varying numbers or cells per ampule, starting from >25 million cells.

Online: lonzabioscience.com.au
Phone: 1300 657508

Content from other channels on our network

National concussion clinical guidelines now available

Eye care partnership looks to support First Nations optometrists

How are AI models approved for use in health care?

$910m new Rouse Hill Hospital — designs released

What is My Health Record? For healthcare providers

Blending operations boosted using rotary batch mixer

CCEP inspires young workers to create influential change

Helen Strachan appointed Chair of Australian Grape & Wine

Boosting plant-based protein manufacturing in regional NSW

High-protein concepts on show in Paris

Concrete repair key to sustainability

Signposting the way to a regenerative economy

Pledges favour land-based carbon removal over emission cuts

Epson opens smart factory with Citizen Wolf

MSCI report shows rising climate risks

Lonza bone marrow and cord blood mononuclear cells

ProImmune ProVE SL Self-Loading MHC Class I Monomers

HAWK Biosystems Quantifying Functions in Proteins (QF-Pro) reagent kits

Amsbio validated cytokines for organoid culture

Content from other channels on our network